Three hundred and ®fty-three patients with symptomatic benign prostatic hyperplasia were randomized to doxazosin or placebo, with morning or evening dosing, to compare the effect of dosing time on the ef®cacy and safety of doxazosin treatment. After 24 weeks of treatment, the mean International Prostate Symptom Score had decreased by 6.8 units in the doxazosin group compared with 4.5 units in the placebo group (P 0.003). Improvements in Q max of 2.03 mlas and 0.30 mlas were seen for the doxazosin and the placebo groups, respectively (P`0.001). No differences in ef®cacy or safety between the morningand evening-dosed subgroups were observed. Doxazosin was signi®cantly more effective than placebo at improving symptoms of BPH and urinary¯ow rates at endpoint, and was well tolerated. The time of dosing did not appear to in¯uence the ef®cacy or safety of doxazosin, suggesting that there is no need to restrict administration of doxazosin to the evening in BPH patients.
Introduction
Benign prostatic hyperplasia (BPH) is a common disease in older men and has increased prevalence with advancing age. 12 The condition may result in benign prostatic enlargement and urethral obstruction.
The tone of the prostate smooth muscle is mediated by a 1 -adrenergic receptors. 3 It is thought that the symptoms of BPH result both from mechanical obstruction of the urethra by the enlarging prostate, and a dynamic component which results from sympathetic stimulation of smooth muscle tone. Blocking the a 1 -adrenergic receptors in the prostate results in relaxation of the smooth muscle, decreasing the dynamic component, and contributing to improvements in the symptoms of BPH. 4 A great deal of experience has been obtained with the use of selective a 1 -adrenoceptor antagonists, such as doxazosin, in hypertension, and are recommended as ®rst-line treatment for essential hypertension by the World Health Organization/The International Society of Hypertension 5 and the Joint National Committee on the Detection, Evaluation and Treatment of Hypertension. 6 Various studies have shown that a 1 -adrenoceptor antagonists can alleviate the symptoms of BPH, 4,7±9 and the use of these agents for the treatment of BPH has been endorsed in international guidelines. For example, they are recommended for initial treatment of symptomatic BPH by the International Consultation on BPH 10 and the Agency for Health Care Policy and Research. 11 Traditionally, a 1 -adrenoceptor antagonists have been taken in the evening, a strategy to minimise the potential for adverse events such as dizziness, light headedness and fatigue, which frequently lead to discontinuation of therapy. Compliance may be improved if the patient has the freedom to choose when to take the medication, that is in the morning or evening. In patients with nocturia, morning dosing may be preferable because of the concern that some patients may experience postural hypotension with evening dosing if they have get up quickly during the night. Doxazosin is a highly selective a 1 -adrenoceptor antagonist with high af®nity for all a 1 -adrenoceptor subtypes, including the a 1A (formerly known as a 1C )-subtype which is thought to be predominant and functional in the prostate. 12 Doxazosin has been shown to be effective and well tolerated in the treatment of BPH. 7,9,13±16 It has the longest half-life of the presently marketed a-blockers; therefore, it is suitable for once daily dosing. Vashi et al 17 have shown that the pharmacokinetics of doxazosin are comparable when the drug is taken in the morning or evening.
In the majority of studies to date, the time of administration of doxazosin was not designated, either morning or evening dosage was allowed. A pilot study has attempted to compare the ef®cacy and safety of morning dosing with evening dosing of a 1 -adrenoceptor antagonists in patients with BPH.
18±19 This, however, is the ®rst prospective, placebo-controlled study to compare ef®cacy and safety of morning and evening dosing using a longacting a 1 -adrenoceptor antagonist in a large number of patients with symptomatic BPH.
Methods

Patient selection
Male patients, aged 50±80 y, with an International Prostate Symptom Score (I-PSS) of ! 12 and a maximum urinary¯ow rate (Q max ) of between 5 and 12 ml/s in a total voided volume of ! 150 ml, were eligible for this study. Both hypertensive and normotensive patients could be entered. All patients were required to provide written informed consent.
Patients were excluded from the study if they had previous prostate surgery; any co-existing condition that may affect micturition, such as neurogenic bladder, bladder neck contracture, urethral stricture, urinary tract infection (UTI), bladder cancer, or acute or chronic prostatitis; acute urinary retention; bladder stones; recurrent UTI; large bladder diverticulum; a residual urine volume of b200 ml; prostate malignancy; or, a prostate speci®c antigen (PSA) concentration of ! 10 ng/ml unless biopsy had ruled out prostate cancer. Other exclusion criteria included other signi®cant medical conditions or clinically signi®cant hypotension (blood pressure`95/60 mmHg).
Patients were not permitted to take concomitant medication with agents known to affect vesico-urethral function during the study and any treatment with b-blockers or diuretics had to be stabilised at least four weeks before entering the trial.
Study design
This was a 26-week, double-blind, placebo-controlled, randomized, prospective, multi-centre study performed in 28 centres in the UK. Following a two-week singleblind, placebo run-in period, baseline values were established and patients were randomized in a double-blind manner at a ratio of 2 : 1 to receive doxazosin or matched placebo. The patients in each group were then further randomized in equal proportions to either morning (8.00 am) or evening (before retiring to bed) dosing. An initial dose of 1 mg doxazosin or matching placebo was given daily for two weeks post randomisation and then increased to 2 mg daily for the next 10 weeks. At this point (week 12), if the patient had not responded to treatment (de®ned as a decrease in I-PSS of ! 30% or an increase in Q max of ! 3 ml/s compared with baseline), the dose could be increased to 4 mg daily.
Whatever dose the patient was receiving at this point was maintained until the end of the 24-week treatment period unless prolonged adverse events or a decrease in blood pressure to`90/60 mmHg occurred, in which case the 4 mg dose was reduced to 2 mg daily. Patients who were unable to tolerate 2 mg daily were withdrawn from the study.
The primary ef®cacy parameters were I-PSS and Q max . The I-PSS consists of seven items based on the symptoms of BPH, each rated on a scale of 0 (not experienced at all) to 5 (experienced almost always). All patients were assessed during the day and after the 8.00 am dose was taken by patients receiving morning dosing. Urinary¯ow rates, measured using the Dantec Urodyn 1000 rotatinḡ ow meter, were the average of two separate measurements taken from a total voided volume of ! 150 ml. All¯ow traces were read blindly at a central location. I-PSS index, Q max , and mean urinary¯ow rate (Q mean ) were determined at the initial visit, at baseline after the two-week placebo run-in period, and at 6, 12 and 24 weeks.
A simple assessment of quality of life due to urinary symptoms was also made at each visit. Patients were asked how they would feel if their condition remained as it was at that point for the rest of their life, and this was scored from 0 (delighted) to 6 (terrible).
Safety was assessed at each clinic visit (baseline and at 2, 4, 6, 12, 18, and 24 weeks of randomized therapy) and also at 14 weeks for patients who received a dosage increase at 12 weeks. Assessments included sitting and standing blood pressure, heart rate, body weight, and the occurrence of adverse events. Blood count and blood chemistry, urinalysis, ECG and PSA concentrations were also assessed at baseline and at 24 weeks (or at endpoint).
Statistical analysis
All patients who had received active therapy and had attended at least one post-treatment assessment at which ef®cacy data were obtained were included in the statistical analysis. All patients included had adhered to the study protocol except that patients had a baseline Q max of between 5 and 20 ml/s, instead of between 5 and 12 ml/s as de®ned in the protocol. Additionally, only patients with compliance violations were totally excluded from the analysis; patients with other protocol violations had only the visits affected by the violation excluded. The baseline value for all ef®cacy variables was the mean of the measurements taken at the end of the placebo run-in period. Observed means were used for within treatment comparisons and adjusted means (the expected value of the mean for the treatment group if the groups were of the same size with the same baseline) from the analysis of variance were used for between treatment comparisons. Ef®cacy, blood pressure and heart rate results were compared among treatments using analysis of co-variance, including effects for baseline, treatment, centre, time of dosing, treatment by centre interaction, and treatment by time interaction. Patient demographic comparability was evaluated using analysis of variance. The incidence of adverse events was compared using w-square tests. All statistical tests were two-tailed and a signi®cance level of 5% was used.
Results
Three hundred and ®fty-three patients were randomized into the study, 234 in the doxazosin group (121 in the morning and 113 in the evening subgroups) and 119 in the placebo group (60 in the morning and 59 in the evening subgroups). No statistically signi®cant differences between groups or subgroups with regard to patient demographics and baseline characteristics were observed ( Table 1 ).
The percentage of normotensive patients (de®ned as a sitting diastolic blood pressure of 90 mmHg) in each group was also comparable (70.9% in the doxazosin group and 71.4% in the placebo group), as was the percentage of patients 65 y or over (56.8% compared with 60.5% in the placebo group).
The mean duration of treatment and mean dose of study drug at endpoint were similar between all four subgroups ( Table 2 ). The overall mean dose (morning and evening subgroups combined) at endpoint for the doxazosin and placebo groups was 3.3 mg and 3.4 mg, respectively. At week 12 the number (percentage) of patients increasing daily dosage to 4 mg was 151 (74.8%) in the doxazosin group and 87 (86.1%) in the placebo group. Of these patients ®ve doxazosin patients and four placebo patients reduced their dose back to 2 mg. The percentage of patients who increased their dose was approximately equal between morning and evening dosing subgroups for each treatment group although the percentage of patients receiving a dosage increase at this time was slightly higher in the placebo subgroups than in the doxazosin subgroups ( Table 2 ). The percentage of doxazosin patients who completed the 24-week study period was similar for the two treatment times; however, in the placebo group 84.7% of patients receiving their medication in the evening completed the study compared with 68.3% of patient receiving morning medication (Table 2) .
Ef®cacy
International prostate symptom score At baseline the I-PSS for the doxazosin and placebo groups was 18.4 and 18.6, respectively, the maximum score possible being 35. At endpoint, overall I-PSS had improved by a mean of 6.8 with doxazosin and 4.5 with placebo (P 0.003; Table 3 and Figure 1a ). A signi®cant difference between treatments was also observed for morning dosing (P 0.012), but not for evening dosing (Table 3) .
Signi®cant reductions from baseline in mean I-PSS were also seen within each treatment group (P`0.001; Figure 1b ) at weeks 6, 12 and 24, and a signi®cant treatment effect was seen at week 24 (P 0.006; Figure  1b ). For morning and evening dosing subgroups, statistically signi®cant differences from baseline were seen with both treatments at weeks 6, 12 and 24, and at endpoint (P`0.001 in all cases except for placebo morning dosing at week 24, P 0.003). Between treatment groups differences were observed for morning dosing at weeks 6 (P 0.043) and 24 (P 0.022). No other between group differences according to time of dosing were observed. Figure 2a shows the proportion of patients demonstrating a clinically signi®cant improvement in I-PSS (de®ned as a b30% reduction in score) at endpoint. Overall 59.8% of patients treated with doxazosin and 43.4% of placebotreated patients, demonstrated an I-PSS response at endpoint. There were similar response rates for the patients a For the morning and evening doxazosin subgroups, n 115 and 108, respectively, and n 57 for both placebo subgroups.
b Percentage values calculated from the number of patients remaining in each group at week 12; for morning and evening subgroups n 108 and 94, respectively, for doxazosin patients, and n 49 and 52, respectively, for placebo patients. receiving medication in the morning or evening (57.4% compared with 62.6%, respectively, for the doxazosin group and 42.6% compared with 44.2%, respectively, for the placebo group at endpoint; Figure 2a ). The overall percentage of responders at week 12 was 48.4% (doxazosin) and 42.4% (placebo), whilst at endpoint the respective percentages were 59.8% and 43.4% (Figure 2b ).
Uro¯ow
The measured urinary¯ow parameters at baseline and endpoint, and also the adjusted mean change between these time points, are given in Table 3 . Changes in Q max and Q mean between baseline and week 24 are given in Figure 3 . At endpoint, doxazosin treatment gave statistically signi®cant increases in both Q max and Q mean compared with baseline (P`0.001), irrespective of time of dosing. Treatment with doxazosin was also signi®cantly better than placebo with an overall improvement in Q max of 2.03 ml/s and 0.30 ml/s, respectively (P`0.05). At week 6 both treatments showed signi®cant increases in Q max and Q mean compared with baseline (P`0.001 for doxazosin and P 0.004 for placebo for each parameter) but differences between groups were signi®cant only for Q max (P 0.036). At weeks 12 and 24 doxazosin treatment gave signi®cantly greater increases in Q max and Q mean compared with baseline and placebo (P`0.001 in all cases; Figure 3 ). The bene®cial effects of doxazosin on Q max and Q mean did not appear to be in¯uenced by time of administration. A statistically signi®cant improvement (P`0.05) in Q max and Q mean was observed for both doxazosin subgroups compared with their respective placebo subgroups at endpoint.
At endpoint, the percentage of patients who demonstrated a Q max response (de®ned as an increase in Q max of ! 3 ml/s) was 29.1% in the doxazosin group compared with 14.7% in the placebo group (Figure 2a) . However, the statistical difference between groups was not analysed. The response rate at endpoint was comparable for morning (29.7%) and evening (28.4%) treated doxazosin patients, whilst for placebo patients the percentage of responders following morning (16.7%) dosing was slightly larger than following evening (13.0%) dosing. Differences in mean change in I-PSS between doxazosin and placebo were signi®cant for morning (P 0.012) and overall (P 0.003) dosing. Differences in mean change in Q max and Q mean between doxazosin and placebo were signi®cant for morning (P`0.015), evening (P`0.001), and overall (P`0.001) dosing. The percentage of responders at week 12 and at endpoint were 23.4% and 29.1%, respectively, for doxazosin and 14.0% and 14.7%, respectively, for placebo ( Figure 2b ).
Overall treatment response
Overall, the percentage of patients who were considered to have a clinically signi®cant response to treatment was 70.6% in the doxazosin group and 47.5% in the placebo group. Again, time of dosing did not affect the overall response rate: at endpoint, 70.4% of morning-dosed and 70.8% of evening-dosed doxazosin patients responded to treatment.
Quality of life
Patients in both treatment groups reported a signi®cant improvement in quality of life due to urinary symptoms during the course of the study (endpoint versus baseline, P`0.001 for both groups). At endpoint, a greater mean change in quality of life was observed for the doxazosin group (mean change in questionnaire results of À1.1) compared with placebo (mean change of À0.8), although this did not reach statistical signi®cance (P 0.087). For the doxazosin group at endpoint, 17.7% of patients were pleased or delighted, and 25.4% were mostly satis®ed with their condition. The corresponding values for the placebo group were 11.9% and 21.8%. There were no differences in improvements in quality of life between morning and evening dosing for either the doxazosin group (P 0.43) or placebo group (P 0.649).
Safety Adverse events
The proportion of patients reporting adverse events was similar for the doxazosin and placebo groups and did not appear to be in¯uenced by time of dosing ( Figure 4 and Table 4 ). The proportion of patients with treatmentrelated adverse events (as assessed by the investigator) was 26.9% in the doxazosin group and 22.7% in the placebo group. Treatment-related adverse events following evening dosing were reported by 30.1% and 23.7% of patients receiving doxazosin and placebo, respectively, compared with 24.0% and 21.7%, respectively following morning dosing (Figure 4 ), the differences however, were not clinically signi®cant and were not statistically analysed. Table 4 summarises the most commonly reported adverse events for the two treatment groups and times of dosing. Most were mild to moderate in intensity and were tolerated, or disappeared with continued treatment. The incidence of postural adverse events (syncope, postural hypotension and postural dizziness) was low in both the doxazosin group (3.0%) and the placebo group (2.5%) and did not differ with time of dosing.
The most frequently occurring adverse events in the doxazosin treatment group were headache and dizziness (Table 4) . These were two of the four most commonly reported adverse events in the placebo group. These two adverse events occurred in twice as many evening-dosed doxazosin patients as morning-dosed. The evening-dosed placebo subgroup also demonstrated a higher frequency of dizziness than the morning-dosed subgroup but a greater number of patients reported headache following morning dosing. For doxazosin patients the incidence of all other adverse events was similar between morning and evening subgroups. The incidence of severe adverse events was low and comparable for the doxazosin and placebo groups (20 [ (Figure 4 ). Of these, in the doxazosin group, nine patients (7.4%) withdrew following morning dosing and 15 patients (13.3%) after evening dosing. The corresponding number of withdrawals in the placebo group were eight (13.3%) and four (6.8%) patients, respectively.
Vital signs
Small, but a signi®cant (P`0.05) reduction in both sitting and standing blood pressure from baseline were observed following doxazosin treatment but not with placebo. Mean sitting blood pressure in the doxazosin group was reduced from a mean of 141/85 mmHg at baseline to 134/81 mmHg at endpoint (change of 7/4 mmHg) and standing blood pressure was reduced from a mean of 140/87 mmHg to 133/82 mmHg (change of 7/5 mmHg). In the placebo group the mean blood pressure changes were 1/2 mmHg whilst sitting and 1/1 mmHg whilst standing. Differences between treatments were also statistically signi®cant (P`0.05 for both sitting and standing blood pressure). There were no statistically signi®cant differences in blood pressure reductions for the morning, compared with the evening-dosed subgroups. Neither treatment had any effect on heart rate.
Laboratory parameters
No clinically signi®cant changes were observed in any of the laboratory parameters investigated (including ECG) and the time of dosing had no effect on any of these parameters. Figure 3 (a) Mean change AE s.e.m. in maximum¯ow rate in the doxazosin and placebo groups over the 24-week study period. In the doxazosin group at each time point maximum¯ow rate was signi®cantly improved from baseline (P`0.001). In the placebo group a signi®cant improvement was only seen at week 6 (P 0.004). Signi®cant differences between treatment groups was observed at each time point, P 0.036 (*) or 0.001 (**). Patient numbers at 6, 12 and 24 weeks were 185, 188 and 171 in the doxazosin group and 98, 93 and 82 in the placebo group. (b) Mean change AE s.e.m. in mean¯ow rate in the doxazosin and placebo groups over the 24-week study period. In the doxazosin group at each time point maximum¯ow rate was signi®cantly improved from baseline (P`0.001), but for the placebo group a signi®cant improvement was only seen at week 6 (P 0.004). Signi®cant differences between treatment groups was observed at weeks 12 and 24, P`0.001 (*). Patient numbers at 6, 12 and 24 weeks were 185, 188 and 171 in the doxazosin group and 98, 93 and 82 in the placebo group. Figure 4 The percentage of patients exhibiting adverse events and discontinuing the study because of adverse events in the doxazosin and placebo groups for the morning and evening dosage schedules.
Discussion
The results of this 26-week, double-blind, placebo-controlled study in patients with symptomatic BPH indicate that doxazosin at a mean dose of 3.3 mg daily (at endpoint) was more effective than placebo in providing symptomatic bene®t and improving urinary¯ow in these patients. The improvement in primary ef®cacy variables was statistically signi®cant for I-PSS following morning dosing and for Q max following morning and evening dosing. At endpoint, I-PSS had improved by a mean of 6.8 in the doxazosin group compared with 4.5 in the placebo group, and Q max had improved by a mean of 2.03 ml/s in the doxazosin group compared with 0.30 ml/s in the placebo group. In addition, the proportion of patients with a clinically signi®cant response to treatment at endpoint appeared to be greater in the doxazosin group (70.6%) than in the placebo group (47.5%).
Meaningful comparisons between the results of this study and other studies evaluating a 1 -adrenoceptor antagonists in BPH is dif®cult due to differences in methodology and patient characteristics. However, improvements of a similar magnitude to those seen in this study have been observed in other studies with doxazosin 7,9,13±16 and with other a 1 -adrenoceptor antagonists. 4,8,20±22 The dose range of doxazosin used in the present study has been shown to be effective in a large number of clinical trials, and is that recommended by its manufacturers (2±4 mg). Although doxazosin has been shown to be effective at doses greater than 4 mg, in actual practice, the number of patients prescribed doxazosin at doses greater than 4 mg is neglible.
The clinical improvement induced by traditional a 1 -adrenoceptor antagonists in some BPH patients may be offset by adverse events, most commonly dizziness, light headedness and fatigue, and evening dosing has been considered preferable to minimise these effects. Adverse effects are, however, observed less commonly in newer agents with longer half-lives, such as doxazosin (halflife approximately 22 h). This study has demonstrated that doxazosin at a dose of 2±4 mg daily either in the morning or evening was well tolerated in patients with BPH. The overall incidence of adverse effects and those considered by the investigator to be related to study medication was comparable for the doxazosin and placebo groups. Most adverse events were mild to moderate in severity and were tolerated or disappeared with further treatment. As with studies evaluating other a 1 -adrenoceptor antagonists, 14, 23 dizziness and headache were among the most commonly reported adverse events during the trial; the incidence of these, however, was low and did not differ between the doxazosin and placebo groups. Only two adverse events, again dizziness and headache, appeared to occur at a higher frequency following evening dosing with doxazosin; a higher incidence of dizziness was also seen with placebo. It should be noted that these effects were in general of mild to moderate intensity and disappeared or were tolerated with further treatment. The reason for the larger number of adverse events following evening dosing is unclear. Although it could be argued that the difference is due to the morning and evening dosing being nonblinded, a time of day effect is a more likely explanation. There were no differences between the morning and evening subgroups in the changes in sitting and standing blood pressure. These ®ndings demonstrate that the administration of doxazosin does not have to be restricted to the evening. The option to choose when to take this once-daily medication may improve patient compliance.
BPH patients with nocturia, a common symptom, are considered at particular risk of the postural orthostatic adverse effects associated with most a 1 -adrenoceptor antagonists, especially following evening dosing, since such patients frequently get out of bed quickly during the night. Few orthostatic effects have been seen with doxazosin compared with earlier a 1 -adrenoceptor antagonists such as prazosin: this may be because doxazosin has a longer duration of action and a more gradual onset of action (2±4 h to peak concentration) and therefore abrupt falls in blood pressure are avoided. 23, 24 In the present study, the incidence of postural adverse events, including syncope, postural hypotension and postural dizziness, was low in doxazosin (3.0%) and placebo (2.5%) groups and did not differ between morning and evening dosage subgroups. Doxazosin can, therefore, be given in either the morning or the evening without orthostatic complications. Long-term treatment of BPH is often desirable. The present study shows that with continued administration of doxazosin, ef®cacy is maintained for at least 24 weeks: I-PSS had improved signi®cantly by 6 weeks and remained signi®cantly reduced at weeks 12 and 24. In addition, the incidence of adverse events was similar to that seen in earlier shorter trials. 7,9,13,14 Lepor 25 has shown in an open-label extension study, that doxazosin-induced improvements in symptoms and Q max could be sustained for up to 48 months without any changes in the type or severity of adverse events reported.
The observed reductions in mean sitting and standing blood pressure following doxazosin treatment were comparable with those reported for other a 1 -adrenoceptor antagonists in BPH. 4 Although a separate analysis of the 29% of patients in the doxazosin group who were hypertensive at baseline was not carried out, these patients should bene®t from reductions in blood pressure. It has been estimated that up to 25% of the male population over the age of 60 y may suffer from BPH and hypertension, 26 so it would be bene®cial to treat patients with one agent which is active for both conditions.
A pilot study has evaluated the effects of morning and evening dosing of doxazosin in 43±48 normotensive BPH patients over 3±19 months. 18, 19 Results indicated that ef®cacy was not affected by time of dosing. In contrast to the present study, however, the incidence of adverse events was lower with evening dosage and this may be explained by the small number of patients in the study. Indeed, the pilot study concluded that a larger prospective trial was required to determine optimal timing of dosage. There have been no other reports of studies evaluating the relative effects of morning or evening dosing regimens of long-acting a 1 -adrenoceptor antagonists on clinical ef®cacy and safety in patients with BPH, although Lepor et al, 21 have suggested that terazosininduced fatigue in patients with BPH may be reduced by administering the drug at bedtime.
Finally, some previous studies have been criticized in that the sizes of the prostates of patients at entry have been too small to be con®dent of a diagnosis of BPH. It should be noted that the entry criteria for patients in the present study were clearly de®ned with relation to their I-PSS score and Q max rate, and not to their prostate size. Moreover, the Agency for Health Care Policy and Research current guidelines for BPH 11 recommend that the size of prostate should not be considered in deciding whether active treatment should be given, since prostate size does not correlate with symptom severity, degree of urodynamic obstruction, or treatment outcomes.
Conclusions
Doxazosin was signi®cantly more effective than placebo at improving urinary¯ow rates and symptoms of BPH and was well tolerated. The results of this study show that the time of dosage of doxazosin (morning or evening) does not in¯uence the drug's ef®cacy or safety and that there is no need to restrict dosing to the evening. The choice of dosage time, along with the once-daily administration afforded by the long half-life (22 h) of doxazosin may help to maximise patient compliance, when compared with other dosing regimens.
